Roche, Cepheid Execs Wrangle over Clinical Market for PCR-based MRSA Tests
July 29, 2010
Roche, Cepheid Execs Wrangle over Clinical Market for PCR-based MRSA Tests
On the heels of both Roche and Cepheid receiving 510(k) approval from the US Food and Drug Administration for PCR-based nasal swab tests for methicillin-resistant Staphylococcus aureus, executives from both companies traded barbs related to their competitive position within the burgeoning market.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - FDA Clears Roche’s PCR-Based MRSA Nasal Test
July 15, 2010 / PCR Insider - On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider - Cepheid Recalls MRSA Blood Culture Test for Second Time; Company, Analysts Unconcerned
January 12, 2012 / PCR Insider - Cepheid Terminates Roche PCR License; Reports Record Revenues in Q3 2011
October 20, 2011 / PCR Insider